Dyne Therapeutics (DYN) Stock Forecast, Price Target & Predictions
DYN Stock Forecast
Dyne Therapeutics stock forecast is as follows: an average price target of $49.00 (represents a 104.25% upside from DYN’s last price of $23.99) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
DYN Price Target
The average price target for Dyne Therapeutics (DYN) is $49.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $53.00 to $42.00. This represents a potential 104.25% upside from DYN's last price of $23.99.
DYN Analyst Ratings
According to 8 Wall Street analysts, Dyne Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DYN stock is 1 'Strong Buy' (12.50%), 7 'Buy' (87.50%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dyne Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Michael Ulz | Morgan Stanley | $52.00 | $43.64 | 19.16% | 116.76% |
| Aug 13, 2024 | Edward Tenthoff | Piper Sandler | $53.00 | $43.07 | 23.06% | 120.93% |
| Jun 24, 2024 | Eun Yang | Jefferies | $42.00 | $35.94 | 16.86% | 75.07% |
| Jun 17, 2024 | Francois Brisebois | Oppenheimer | $55.00 | $32.15 | 71.07% | 129.26% |
| May 21, 2024 | Keay Nakae | Chardan Capital | $42.00 | $35.38 | 18.71% | 75.07% |
| May 20, 2024 | Andrew Fein | H.C. Wainwright | $48.00 | $33.83 | 41.91% | 100.08% |
| May 20, 2024 | Paul Matteis | Stifel Nicolaus | $41.00 | $27.68 | 48.12% | 70.90% |
| Apr 30, 2024 | Michael Ulz | Morgan Stanley | $40.00 | $25.46 | 57.11% | 66.74% |
| Nov 29, 2022 | J.P. Morgan | $18.00 | $10.46 | 72.08% | -24.97% | |
| Sep 06, 2022 | Edward Tenthoff | Piper Sandler | $23.00 | $11.60 | 98.28% | -4.13% |
| Jul 12, 2022 | Edward Tenthoff | Piper Sandler | $17.00 | $9.03 | 88.26% | -29.14% |
The latest Dyne Therapeutics stock forecast, released on Aug 14, 2024 by Michael Ulz from Morgan Stanley, set a price target of $52.00, which represents a 19.16% increase from the stock price at the time of the forecast ($43.64), and a 116.76% increase from DYN last price ($23.99).
Dyne Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 8 |
| Avg Price Target | - | - | $46.63 |
| Last Closing Price | $23.99 | $23.99 | $23.99 |
| Upside/Downside | -100.00% | -100.00% | 94.37% |
In the current month, the average price target of Dyne Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dyne Therapeutics's last price of $23.99. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 14, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Jefferies | Buy | Buy | Hold |
| Jun 17, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 20, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 20, 2024 | Jefferies | Buy | Buy | Hold |
| May 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 20, 2024 | Guggenheim | Buy | Buy | Hold |
| Apr 30, 2024 | Morgan Stanley | Overweight | Initialise | |
| Mar 08, 2024 | Chardan Capital | Buy | Buy | Hold |
| Mar 06, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Feb 27, 2023 | Raymond James | Strong Buy | Upgrade | |
| Sep 06, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 12, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Dyne Therapeutics's last stock rating was published by Piper Sandler on Sep 23, 2024. The company gave DYN a "Overweight" rating, the same as its previous rate.
Dyne Therapeutics Financial Forecast
Dyne Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $1.67M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $1.67M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $1.67M |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DYN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Dyne Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict DYN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Dyne Therapeutics's previous annual EBITDA (undefined) of $NaN.
Dyne Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-90.79M | $-92.81M | $-92.81M | $-92.81M | $-97.73M | $-95.21M | $-93.82M | $-91.30M | $-94.66M | $-71.82M | $-66.39M | $-80.71M |
| High Forecast | $-90.79M | $-92.81M | $-92.81M | $-92.81M | $-97.73M | $-95.21M | $-93.82M | $-76.94M | $-75.11M | $-71.82M | $-66.39M | $-80.71M |
| Low Forecast | $-90.79M | $-92.81M | $-92.81M | $-92.81M | $-97.73M | $-95.21M | $-93.82M | $-107.71M | $-111.12M | $-71.82M | $-66.39M | $-80.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DYN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Dyne Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DYN last annual SG&A of $NaN (undefined).
Dyne Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.90 | $-0.92 | $-0.92 | $-0.92 | $-0.97 | $-0.94 | $-0.93 | $-0.91 | $-0.94 | $-0.71 | $-0.72 | $-0.80 |
| High Forecast | $-0.90 | $-0.92 | $-0.92 | $-0.92 | $-0.97 | $-0.94 | $-0.93 | $-0.76 | $-0.74 | $-0.71 | $-0.72 | $-0.80 |
| Low Forecast | $-0.90 | $-0.92 | $-0.92 | $-0.92 | $-0.97 | $-0.94 | $-0.93 | $-1.07 | $-1.10 | $-0.71 | $-0.72 | $-0.80 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Dyne Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DYN previous annual EPS of $NaN (undefined).
Dyne Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| CYTK | Cytokinetics | $47.78 | $90.00 | 88.36% | Buy |
| DYN | Dyne Therapeutics | $26.16 | $49.00 | 87.31% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |